SCHEMBL587387

SCHEMBL587387

CC(Cl)c1ccccc1S(=O)(=O)c1ccccc1C(C)Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.44
MMP9 P14780 4/20 0.44
MMP8 P22894 4/20 0.44
MMP12 P39900 4/20 0.44
MMP13 P45452 4/20 0.44
MMP14 P50281 4/20 0.44
MMP16 P51512 4/20 0.44
MMP1 P03956 2/20 0.44
GAA P10253 1/20 0.41
HSD11B1 P28845 2/20 0.41
MMP3 P08254 3/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
KCNH2 Q12809 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10645229 0.85 ALDH1A1 (0.38) MMP2MMP9MMP8MMP12MMP13
SCHEMBL10641489 0.83 CA2 (0.47) CA12CA1CA2CA9
SCHEMBL9379437 0.82 HSD11B1 (0.54) MMP2MMP9MMP8MMP12MMP13
SCHEMBL6680955 0.78 GAA (0.46) MMP2MMP9MMP8MMP12MMP13
SCHEMBL2865478 0.75 GABRA1 (0.43) HTR2CL3MBTL1ALDH1A1LMNAHPGD
SCHEMBL5957556 0.74 TRPV4 (0.41) GAAALDH1A1LMNATP53CYP3A4
Oxalic Acid SCHEMBL8940966 0.74 MMP2 (0.51) MMP2MMP9MMP8MMP12MMP13
SCHEMBL719364 0.73 GAA (0.44) MMP2MMP9MMP8MMP12MMP13
SCHEMBL27718757 0.72 GABRA1 (0.55) MMP2MMP9MMP8MMP12MMP13
SCHEMBL5757186 0.72 PSEN1 (0.47) HTR2AHTR2CKCNH2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118763273-A Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof 青岛赛锂达储能产业技术研究院有限公司 2024-10-11 CN claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
CN-118763273-A Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof 青岛赛锂达储能产业技术研究院有限公司 2024-10-11 CN disclosed
CN-105175397-A Synthesis method of eletriptan hydrobromate SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD 2015-12-23 CN disclosed
US-20120071669-A1 PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF USV Limited B.S.D. Mar (IN) 2012-03-22 US disclosed
US-8115046-B2 Micro encapsulation composition for hydrocarbons and detoxification of highly hazardous chemicals and substances RTA SYSTEMS, INC. (US) 2012-02-14 US disclosed
US-7951826-B2 Obesity; cognition activators; narcolepsy ELI LILLY AND COMPANY (US) 2011-05-31 US disclosed
EP-1861360-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-12-02 EP disclosed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US disclosed
US-4895840-A ANTIARRHYTHMIA AGENTS A. H. ROBINS COMPANY, INCORPORATED (US) 1990-01-23 US disclosed
EP-0295010-A1 Derivatives of alkylaminoalkyl ureas and cyanoguanidines A.H. ROBINS COMPANY, INCORPORATED (US) 1988-12-14 EP disclosed
US-4724235-A N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia A. H. ROBINS COMPANY, INCORPORATED (US) 1988-02-09 US disclosed
US-4597902-A TREATMENT OF CARDIAC ARRHYTHMIAS A. H. ROBINS COMPANY, INCORPORATED (US) 1986-07-01 US disclosed
EP-0066415-B1 N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS A.H. ROBINS COMPANY, INCORPORATED (US) 1985-10-02 EP disclosed
EP-0066415-A2 N-(arylthioalkyl)-N'-(aminoalkyl)ureas A.H. ROBINS COMPANY, INCORPORATED (US) 1982-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071669-A1 PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF HTR3C, SLC6A4, HTR3A MMP2 775/4885MMP9 206/4885MMP8 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.